Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655292 | 0.92 | MAOA (0.70) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL13939808 | 0.87 | MAOA (0.80) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL5656356 | 0.87 | MAOA (0.66) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL14525405 | 0.86 | MAOA (0.69) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL5657378 | 0.85 | MAOA (0.64) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL14525401 | 0.85 | MAOA (0.65) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL5658913 | 0.85 | MAOA (0.71) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL5656294 | 0.85 | MAOA (0.64) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL5657686 | 0.85 | MAOA (0.67) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL5657004 | 0.84 | MAOA (0.66) | MAOAKCNH2MAOBCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182112-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| EP-1480975-A2 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-12-01 | — | — | EP | claimed |
| WO-2003072576-A2 | OXAZOLIDINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | claimed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20050182112-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182112-A1 | Chemical compounds | CYP8B1, H1-0, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOA 470/4885KCNH2 360/4885MAOB 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.